PRODUCTS SOLD BY ASCEND PEPTIDES ARE INTENDED FOR RESEARCH USE ONLY.
Laboratory research material
⚠ Important – Acetic Acid Water (AA Water) Handling Notice
Previous product handling guidance identified Acetic Acid Water (AA Water) for this material. The manufacturer-specific solvent requirement is awaiting verification.
Do not assume that bacteriostatic water is interchangeable. Follow a validated laboratory protocol.
For laboratory research only. Not for human use.
CJC-1295 (also written CJC1295) Without DAC 10mg research peptide (Mod GRF 1-29) is a 29-amino-acid GHRH(1-29) analogue with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27), studied as a GHRH receptor (GHRHR) agonist in laboratory research. A Janoshik report is published for a tested batch. Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri). Research use only.
Research guides: CJC-1295 Without DAC research guide · With DAC vs Without DAC
Form: Lyophilized peptide powder
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
CJC-1295 WITHOUT DAC 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
CJC-1295 (Without DAC) 10 mg:
View Janoshik report #125386 (tested sample: CJC1295 without DAC 10mg)
This report covers one tested sample. It does not establish that current stock comes from the same batch.
CJC-1295 Without DAC 10mg Research Peptide UK
CJC-1295 Without DAC 10mg, commercially known as Mod GRF 1-29, is a synthetic 29-amino acid analogue of Growth Hormone Releasing Hormone (GHRH) with four substitutions (D-Ala2, Gln8, Ala15 and Leu27). D-Ala2 makes it more resistant to DPP-IV cleavage than unmodified GRF(1-29) (Sermorelin 2mg). Molecular weight approximately 3,367 Da; it is a GHRH receptor agonist.
Upon GHRHR binding, CJC-1295 without DAC 10mg initiates the cAMP and PKA signalling cascade. The non-DAC form is substantially shorter-acting than the albumin-binding DAC-modified form, while retaining the tetrasubstituted GRF(1-29) analogue structure described in the research literature.
CJC-1295 Without DAC 10mg is often studied alongside Ipamorelin 5mg or Ipamorelin 10mg. These two compounds target mechanistically distinct receptors: CJC-1295 without DAC targets GHRHR, while ipamorelin targets GHS-R1a (the ghrelin receptor). Both increase GH release, and combined GHRH and GHRP stimulation can interact, so in the same experimental system they are not independent variables and combined arms need appropriate controls.
For researchers comparing GHRH analogue structures, this compound can be studied alongside CJC-1295 with DAC 10mg (extended-release DAC modification), Sermorelin 2mg (unmodified GRF(1-29) sequence), and Tesamorelin 5mg (full 44-amino acid GHRH sequence). Mechanism background and published references are available in the CJC-1295 Without DAC research guide on the Ascend Peptides UK blog. For a structural comparison of both variants, see our CJC-1295 With DAC vs Without DAC comparison guide.
Name and evidence status: the name CJC-1295 was first given to the DAC (albumin-binding) compound tested in healthy adults by Teichman et al. (J Clin Endocrinol Metab, 2006). “CJC-1295 Without DAC” is a trade name for the unconjugated Mod GRF 1-29 peptide, so those human results, including the multi-day half-life, do not apply to this product. No published human trials of the non-DAC peptide were identified in the sources reviewed, and these data do not describe or verify the research material supplied here.
A CJC-1295 Without DAC 10mg batch has been independently tested by Janoshik. Its published Certificate of Analysis reports measured content and purity for that batch and is available for independent verification. LC-MS identity data is not separately reported on the published certificate.
Storage requirements for CJC-1295 Without DAC are being confirmed with the manufacturer. Please contact ASCEND for the information held for the current stock.
Prohibited at all times under WADA and UKAD regulations.
For in-vitro laboratory research only. Not for human consumption. Not an MHRA-licensed medicine.
Other laboratory research materials supplied by Ascend Peptides UK.
UK same working-day dispatch – Secure payment options –
Laboratory research only
© 2026 by Ascend Peptides Uk.
All products sold by Ascend Peptides UK are intended strictly for laboratory research purposes only. Not intended for human consumption or therapeutic use of any kind.
Per product, applied automatically in your bagAuto-applied in your bag
Ordering more? Contact us for larger-volume pricing →